Screener
Sutro Biopharma STRO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value — 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 16,566,803 and 8,584,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 17 | 9 |
| Additional paid-in-capital | 949,636 | 845,475 |
| Accumulated other comprehensive (loss) income | (101) | 19 |
| Accumulated deficit | (1,016,439) | (977,955) |
| Total stockholders’ deficit | (66,887) | (132,452) |
| Total Liabilities and Stockholders’ Deficit | $241,988 | $173,830 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's total equity?
- Sutro Biopharma (STRO) reported total equity of -$66.89M in Q1 2026.
- How has Sutro Biopharma's total equity changed year-over-year?
- Sutro Biopharma's total equity decreased by 159.1% year-over-year, from -$25.81M to -$66.89M.
- What is the long-term trend for Sutro Biopharma's total equity?
- Over 5 years (2020 to 2025), Sutro Biopharma's total equity has grown at a -16.8% compound annual growth rate (CAGR), from $332.05M to -$132.45M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Sutro Biopharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude